Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2004

View Archived Issues

Cardiac chymase: a novel target in post-MI treatment

Action of NS-8 on micturation reflex investigated in rat model

Effective local bone formation and fracture healing by CP-533536

Novel KSP inhibitors identified by Merck researchers

Roche scientists present new MAO-B inhibitors for AD and senile dementia

New antipsychotic agents with 5-HT and dopamine receptor activity

Two series of morpholine-based CCR3 antagonists under study at GSK

New protein kinase inhibitors and their use in cancer therapy reported by Cytopia

A phase III clinical trial confirms the benefits of Prialt in patients with severe chronic pain

Sertraline helps depression and quality of life after hospitalization for acute coronary syndrome

PPD amends dapoxetine license

Akzo Nobel to transfer Arixtra to Sanofi-Synthelabo

Targeted Genetics extends AIDS vaccine partnership

Ranbaxy generic minocycline hydrochloride approved for marketing

Clearance for pivotal Canadian phase IIb/III trial for Tectin

Pfizer advances Atrigel product into further clinical testing

Oraqix receives FDA approval

Nutrition 21 seeks approval of chromium picolinate health benefit claims

Approvable letter for Fortical

Phase I/II trial of MTC-MMC in NSCLC cleared to begin

Alpharma launches generic equivalent of Lotrisone

Prefilled Pegasys syringes approved by FDA

Patient testing completed in phase III Cellegesic trial

LymphoStat-B enters phase II evaluation for active rheumatoid arthritis

Memantine reported effective and safe in patients with mild to moderate Alzheimer's disease

End of patient enrollment announced for two clinical trials with Velac(R) Gel

Favrille completes enrollment in a phase II clinical trial of FavId for fNHL

Ambrisentan enters phase III clinical development

Approval granted to an expanded use of Eloxatin for metastatic colorectal cancer in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...